Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL98336 | 0.82 | CA12 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1145316 | 0.78 | SLC6A4 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28158455 | 0.78 | CA1 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29768449 | 0.78 | SLC6A4 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16953948 | 0.77 | NQO1 (0.50) | CA12CA1CA7CA9CA14 | |
| SCHEMBL19785375 | 0.76 | HSP90AA1 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL130126 | 0.74 | MCL1 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14697809 | 0.74 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL196970 | 0.74 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL322093 | 0.74 | CA12 (0.46) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3641776-A1 | ATROPISOMERISM FOR ENHANCED KINASE INHIBITOR SELECTIVITY | San Diego State University Research Foundation (US) | 2020-04-29 | — | — | EP | disclosed |
| WO-2018237134-A1 | ATROPISOMERISM FOR ENHANCED KINASE INHIBITOR SELECTIVITY | SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2018-12-27 | — | — | WO | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| EP-1203766-B1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC (US) | 2012-02-29 | — | — | EP | disclosed |
| CN-101475526-B | Carboxylic acid derivatives inhibiting the binding of integrins to receptors thereof | TEXAS BIOTECHNOLOGY CORP | 2011-05-25 | — | — | CN | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| CN-101475526-A | Carboxylic acid derivatives inhibiting the binding of integrins to receptors thereof | TEXAS BIOTECHNOLOGY CORP (US) | 2009-07-08 | — | — | CN | disclosed |
| EP-1567505-A4 | COMBINATION PRODUCTS WITH CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS AND OTHER THERAPEUTIC COMPOUNDS | SCHERING CORP (US) | 2009-07-01 | — | — | EP | disclosed |
| CN-100491353-C | Carboxylic acid derivatives inhibiting the binding of integrins to their receptors | TEXAS BIOTECHNOLOGIES CORP (US) | 2009-05-27 | — | — | CN | disclosed |
| US-20070060608-A1 | Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds | ENCYSIVE PHARMACEUTICALS INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-6723711-B2 | VASCULAR CELL ADHESION MOLECULES AND FIBRONECTINS; ASTHMA, MULTIPLE SCLEROSIS, ARTHRITIS, INFLAMMATORY BOWEL DISEASE, CONTACT HYPERSENSITIVITY, CARDIAC ALLOGRAFT REJECTION AND DIABETES TREATMENT | TEXAS BIOTECHNOLOGY CORPORATION | 2004-04-20 | — | — | US | disclosed |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| CN-1484638-A | I-aryl-or-I-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-b ligands | — | 2004-03-24 | — | — | CN | disclosed |
| US-20030199692-A1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. | 2003-10-23 | — | — | US | disclosed |
| CN-1412181-A | Carboxylic acid derivatives inhibiting the binding of integrins to their receptors | TEXAS BIOTECHNOLOGIES CORP (US) | 2003-04-23 | — | — | CN | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| EP-1213288-A1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1203766-A2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-05-08 | — | — | EP | disclosed |
| CN-1284075-A | Novel compounds having CGMP-PDE inhibitory effect | MOCHIDA PHARM CO LTD (JP) | 2001-02-14 | — | — | CN | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, FN1 | CA12 1656/4885CA1 1345/4885CA2 1443/4885 |
| US-20070060608-A1 | Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds | VCAM1, ITGB1, ICAM1 | CA12 1056/4885CA1 957/4885CA2 1374/4885 |
| US-20030199692-A1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, FN1 | CA12 3778/4885CA1 2971/4885CA2 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.